A Behavioral Economic Approach to Improving Human Papillomavirus Vaccination

被引:15
|
作者
Caskey, Rachel [1 ,2 ]
Sherman, E. Grace [3 ]
Beskin, Kera [3 ]
Rapport, Rebecca [3 ]
Xia, Yinglin [2 ]
Schwartz, Alan [4 ]
机构
[1] Univ Illinois, Dept Pediat, 840 S Wood St M-C 718, Chicago, IL 60302 USA
[2] Univ Illinois, Dept Med, 840 S Wood St M-C 718, Chicago, IL 60302 USA
[3] Univ Illinois, Sch Publ Hlth, Chicago, IL 60302 USA
[4] Univ Illinois, Dept Med Educ, Chicago, IL 60302 USA
基金
美国国家卫生研究院;
关键词
Human papillomavirus; Vaccination; Immunization; Adolescent immunization; Prevention; UNITED-STATES; INTRAEPITHELIAL NEOPLASIA; FINANCIAL INCENTIVES; QUADRIVALENT VACCINE; CONTROLLED-TRIAL; HPV INFECTION; PREVALENCE; SMOKING; CANCER; STUDENTS;
D O I
10.1016/j.jadohealth.2017.07.020
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Purpose: The objectives of this study were to measure the impact of a behavioral economic intervention on human papillomavirus (HPV) vaccine initiation and series completion rates for adolescents and to measure the impact of the intervention on the receipt of a nonincentivized influenza vaccine. Methods: We conducted a quasi-randomized trial to compare the impact of an escalating delayed cash incentive (intervention), compared with usual care (control), on HPV vaccination initiation and series completion rates among adolescents (11-17 years) at an urban medical center. We measured HPV vaccine initiation and completion rates during the 12 months after enrollment and subsequent influenza vaccination rates for 24 months after enrollment. Results: A total of 85 participants were actively enrolled in the intervention arm and 103 were passively enrolled in the control arm. Participants were predominantly publically insured African-American and Hispanic adolescents. The majority (75%) of the intervention group received one or more doses of the HPV vaccine, with 36% completing the three-dose series, compared with 47% of the control group receiving one or more doses and only 13% completing the series. The odds of HPV p-value vaccine initiation (odds ratio 4.19 [95% confidence interval 1.84-10.10], p < .01) and HPV vaccine series completion (OR 4.16 [95% confidence interval 1.64-11.28], p < .01) were greater among the intervention group compared with the control group. There was no difference in influenza vaccination rates between the intervention group and the control group during the 20132014 season (p = .138) and during the 2014-2015 influenza season (p value .683). Conclusions: An incentive-based approach to HPV vaccination was effective in increasing vaccine initiation and series dose completion. (C) 2017 Society for Adolescent Health and Medicine. All rights reserved.
引用
收藏
页码:755 / 760
页数:6
相关论文
共 50 条
  • [41] Economic evaluation of female vaccination with a quadrivalent human papillomavirus vaccine in New Zealand
    Milne, R. J.
    Vander Hoorn, S.
    Kulasingam, S.
    Tan, A. L.
    VALUE IN HEALTH, 2007, 10 (03) : A6 - A6
  • [42] Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women
    Kahn, Jessica A.
    Rosenthal, Susan L.
    Jin, Yan
    Huang, Bin
    Namakydoust, Azadeh
    Zimet, Gregory D.
    OBSTETRICS AND GYNECOLOGY, 2008, 111 (05): : 1103 - 1110
  • [43] Behavioral Perceptions of Oakland University Female College Students towards Human Papillomavirus Vaccination
    Navalpakam, Aishwarya
    Dany, Mohammed
    Hussein, Inaya Hajj
    PLOS ONE, 2016, 11 (05):
  • [44] The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach
    Chanthavilay, Phetsavanh
    Reinharz, Daniel
    Mayxay, Mayfong
    Phongsavan, Keokedthong
    Marsden, Donald E.
    Moore, Lynne
    White, Lisa J.
    BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [45] The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach
    Phetsavanh Chanthavilay
    Daniel Reinharz
    Mayfong Mayxay
    Keokedthong Phongsavan
    Donald E. Marsden
    Lynne Moore
    Lisa J. White
    BMC Health Services Research, 16
  • [46] The Impact of Human Papillomavirus and Human Papillomavirus Vaccination Among Rheumatology Patients
    O'Connor, Mortimer B.
    Bond, Ursula
    Phelan, Mark J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (07) : 355 - 355
  • [47] Human Papillomavirus Vaccination and Human Papillomavirus-Related Cancer Rates
    Adekanmbi, Victor
    Sokale, Itunu
    Guo, Fangjian
    Ngo, Jessica
    Hoang, Thao N.
    Hsu, Christine D.
    Oluyomi, Abiodun
    Berenson, Abbey B.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [48] Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma
    Colzani, Edoardo
    Johansen, Kari
    Johnson, Helen
    Celentano, Lucia Pastore
    EUROSURVEILLANCE, 2021, 26 (50)
  • [49] Human Papillomavirus: Oral Lesions and Vaccination
    Di Spirito, Federica
    CANCERS, 2023, 15 (10)
  • [50] Human papillomavirus in cervical screening and vaccination
    Crosbie, Emma J.
    Kitchener, Henry C.
    CLINICAL SCIENCE, 2006, 110 (05) : 543 - 552